
The U.S. Food and Drug Administration on Thursday issued new prescribing rules for the controversial Alzheimer’s medication Aduhelm that will likely limit its use. When first approved a month ago, the FDA said Biogen’s monthly IV drug was for all Alzheimer’s patients. The agency now says the drug is appropriate for patients with early or… read on > read on >